Abiomed, Inc. - ABMD STOCK NEWS

Abiomed, Inc. (NASDAQ: ABMD), a frontrunner in heart, lung, and kidney support technologies, has announced that Michael R. Minogue, its Chairman, President, and CEO, will present at the William Blair 42nd Annual Growth Stock Conference. The presentation is scheduled for Monday, June 6, 2022, at 2:00 PM CT. Based in Danvers, Massachusetts, Abiomed specializes in medical devices that enhance blood flow and oxygenation, assisting patients in respiratory failure.

Abiomed (NASDAQ: ABMD) highlights significant advances in heart support technologies at the SCAI 2022 Scientific Sessions, held in Atlanta from May 19-22. A large meta-analysis involving 6,810 acute myocardial infarction cardiogenic shock (AMICS) patients indicates that pre-PCI Impella support correlates with improved short- and mid-term survival rates, reducing mortality from 53.6% to 37.2%. Additionally, the company announces the full market launch of Impella RP with SmartAssist, designed for circulatory support, and FDA approval for a heparin-free sodium bicarbonate purge solution, enhancing patient management.

ABIOMED, Inc. (NASDAQ: ABMD) reported FY 2022 revenue of $1.032 billion, a 22% increase year-over-year. Q4 revenue reached $270 million, up 12% from the prior year. Impella® heart pump product revenue for FY 2022 was $985 million, also up 22%. The company maintained a gross margin of 81.8% and invested $163 million in R&D, a 34% increase. Non-GAAP net income for Q4 was $53 million, or $1.16 per diluted share, increasing from $49 million. For FY 2023, ABIOMED projects revenue between $1.14 billion and $1.18 billion, indicating 11% to 15% growth compared to FY 2022.

Abiomed (NASDAQ: ABMD) has achieved a significant milestone by successfully implanting the first Impella Bridge-to-Recovery (BTR) heart pump in a patient as part of a FDA Early Feasibility Study. This innovative heart pump offers a less invasive option for chronic heart failure patients, promoting recovery and allowing for home discharge. The study aims to evaluate its safety and feasibility over 28 days of support at five hospitals. The first implant was carried out at Northwestern Medicine by Dr. Duc Thinh Pham and Dr. Jane Wilcox.

Abiomed, Inc. (NASDAQ: ABMD) will release its fourth-quarter fiscal 2022 financial results on April 28, 2022, followed by a conference call at 8:00 a.m. ET. CEO Michael R. Minogue and CFO Todd Trapp will lead the discussion. A live webcast can be accessed at investors.abiomed.com. A replay will be available until May 5, 2022. Abiomed specializes in medical devices that support circulatory needs, enhancing heart function.

Abiomed (NASDAQ: ABMD) reports significant advancements with its Impella 5.5 with SmartAssist heart pump, with over 5,000 patients treated globally. The first successful procedure in Japan was conducted at Osaka Police Hospital on an 82-year-old patient. The milestone procedure in the U.S. was performed by Emory University Hospital on a 41-year-old woman. Impella's design enhances minimally invasive surgical options, optimizing patient outcomes with a 74% survival rate to explant. The device is now utilized in over 350 centers in the U.S.

Abiomed, Inc. (NASDAQ: ABMD) will host an investor call on Impella ECP technology on March 29, 2022, from 4:00 p.m. to 5:00 p.m. EDT. The event features presentations from Dr. Amir Kaki and Dr. Charles Simonton, focusing on the FDA Pivotal Trial and case reviews. A live video webcast will be available at https://events.abiomed.com/ImpellaECP and the company's investor section. Abiomed is based in Danvers, Massachusetts, and specializes in circulatory support medical devices.

Abiomed, Inc. (NASDAQ: ABMD), a leader in heart support technologies, announced that CEO Michael R. Minogue will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference. The virtual event is scheduled for February 17, 2022, at 10:40 AM. The company specializes in medical devices aimed at improving blood flow and heart function. Abiomed urges investors to consider potential risks reflected in forward-looking statements and to review their SEC filings for detailed information.

ABIOMED, Inc. (NASDAQ: ABMD) reported robust Q3 2022 results with revenues of $261 million, a 13% increase year-over-year. Impella heart pump revenues reached $249 million, up 13%, driven by a 10% increase in U.S. patient utilization. The company enhanced its fiscal year 2022 revenue guidance to $1,025-$1,030 million, projecting growth of 21%-22%. Non-GAAP net income was $52 million, equating to $1.13 per diluted share. ABIOMED also received multiple regulatory approvals for its Impella products and presented significant clinical data at TCT 2021.